

1. Binding to TF
2. Internalisation of tisotumab vedotin
3. Intracellular trafficking to the lysosomes
4. Enzymatic degradation of tisotumab vedotin, intracellular release of MMAE
5. MMAE induces cell death by microtubule disruption
6. Release of MMAE in tumour microenvironment induces bystander killing of neighbouring cancer cells

FIG. 1

FIG. 2



Screening
Cycle 1
Cycle 2
Cycle 3
Cycle 4+
Disease progression verified by IRC
Death
Treatment (2.0 mg/kg Q3W)[a]
Survival follow-up
CT or MRI scan (Q6W/Q12W)[b]
Baseline CT or MRI scan

FIG. 3



Screened (n=148)
Screen failure (n=46)
• Not meeting eligibility criteria (n=42)
• Other reasons (n=4)
Enrolled (n=102)
Withdrew from trial due to SAE (n=1)
Treated (n=101)
Discontinued treatment (n=97)
• Radiographic disease progression (n=66)
• Adverse event (n=13)
• Clinical progression (n=8)
• Withdrawal of consent/subject request (n=5)
• Death (n=4)
• Investigator decision (n=1)
Ongoing on treatment (n=4)
In survival follow-up (n=33)
Discontinued trial (n=64)
• Death (n=58)
• Withdrawal of consent (n=4)
• Lost to follow-up (n=2)

FIG. 4



Best change
30% decr
% Change from Baseline
100
75
50
25
0
-25
-50
-75
-100
Subject

FIG. 5



+ Censored
Remaining in Response (%)
100
80
60
40
20
0
Time (months)
0
2
4
6
8
10
12
At Risk
24
24
19
14
10
4
0
Median
Subjects DOR 95% CI
24 8.3 4.3 NR

FIG. 6




+ Censored
Progression Free Survival (%)
100
80
60
40
20
0
0
3
6
9
12
15
18
Time (months)
At Risk
101
59
30
18
6
2
0
Median
Subjects PFS 95% CI
101 4.2 3.2 4.6

FIG. 7


+ Censored
Overall Survival (%)
100
80
60
40
20
0
0
3
6
9
12
15
18
Time (months)
At Risk
101
90
77
61
35
8
0
Median
Subjects Survival 95% CI
101 12.1 9.6 13.9